Table 1. COVID-19 symptoms and the onset of neurological manifestations in patients with Miller Fisher syndrome.
| Study | Country | Age (yr) | Sex | COVID-19 symptoms | Onset of neurological manifestations |
|---|---|---|---|---|---|
| Kopscik et al.10 | USA | 31 | M | None | No respiratory symptoms; neurological symptoms were the first sign of SARS-CoV-2 infection |
| Kajani et al.11 | USA | 50 | M | None | No respiratory symptoms; neurological symptoms were the first sign of SARS-CoV-2 infection |
| Manganotti et al.13 | Italy | 50 | F | Fever, cough, dyspnea, and ageusia | 2 weeks after respiratory symptoms (10 days) |
| Rana et al.15 | USA | 54 | M | Fever, chills, odynophagia, rhinorrhea, and dyspnea | 2 weeks after respiratory symptoms (14 days) |
| Assini et al.16 | Italy | 55 | M | Fever, cough, anosmia, and ageusia | 3 weeks after respiratory symptoms (20 days) |
| Dinkin et al.8 | USA | 36 | M | Fever and cough | During the first week of respiratory symptoms (4 days) |
| Fernández-Domínguez et al.4 | Spain | 74 | F | Bilateral pneumonia | 2 weeks after respiratory symptoms (12–15 days) |
| Senel et al.9 | Germany | 61 | M | Fever and mild breathing difficulties | 3 weeks after respiratory symptoms (20 days) |
| Reyes-Bueno et al.12 | Spain | 51 | F | Cough, odynophagia, and diarrhea | 2 weeks after respiratory symptoms (15 days) |
| Gutiérrez-Ortiz et al.3 | Spain | 50 | M | Cough, headache, musculoskeletal pain, fever, anosmia, and ageusia | During the first week of respiratory symptoms (7 days) |
| Ray5 | UK | 63 | M | Fever | No respiratory symptoms; neurological symptoms were the first sign of SARS-CoV-2 infection |
COVID-19, coronavirus disease 2019; F, female; M, male; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.